Zacks: Analysts Expect Kezar Life Sciences Inc (KZR) Will Announce Earnings of -$0.49 Per Share

Share on StockTwits

Wall Street analysts predict that Kezar Life Sciences Inc (NASDAQ:KZR) will post earnings of ($0.49) per share for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Kezar Life Sciences’ earnings. The lowest EPS estimate is ($0.63) and the highest is ($0.35). The business is expected to report its next quarterly earnings results on Thursday, March 28th.

According to Zacks, analysts expect that Kezar Life Sciences will report full year earnings of ($2.37) per share for the current financial year. For the next fiscal year, analysts anticipate that the company will report earnings of ($2.37) per share, with EPS estimates ranging from ($2.84) to ($1.90). Zacks’ EPS calculations are an average based on a survey of sell-side analysts that that provide coverage for Kezar Life Sciences.

Several analysts have recently issued reports on KZR shares. Zacks Investment Research raised shares of Kezar Life Sciences from a “hold” rating to a “buy” rating and set a $29.00 price target on the stock in a research report on Tuesday, November 27th. William Blair reissued an “outperform” rating on shares of Kezar Life Sciences in a research report on Tuesday, March 12th. Finally, ValuEngine lowered shares of Kezar Life Sciences from a “buy” rating to a “hold” rating in a research report on Thursday, December 13th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. Kezar Life Sciences presently has a consensus rating of “Buy” and an average target price of $24.33.

Shares of KZR traded down $1.24 during trading hours on Thursday, hitting $16.83. 64,992 shares of the stock were exchanged, compared to its average volume of 171,568. Kezar Life Sciences has a fifty-two week low of $14.77 and a fifty-two week high of $36.33.

Several hedge funds and other institutional investors have recently bought and sold shares of KZR. New York State Common Retirement Fund bought a new position in shares of Kezar Life Sciences in the 4th quarter worth approximately $73,000. BlackRock Inc. grew its stake in shares of Kezar Life Sciences by 1.9% during the fourth quarter. BlackRock Inc. now owns 245,932 shares of the company’s stock worth $5,804,000 after acquiring an additional 4,486 shares during the last quarter. Northern Trust Corp boosted its position in Kezar Life Sciences by 8.7% in the fourth quarter. Northern Trust Corp now owns 56,993 shares of the company’s stock valued at $1,345,000 after buying an additional 4,581 shares during the last quarter. Slow Capital Inc. purchased a new stake in Kezar Life Sciences in the fourth quarter valued at approximately $216,000. Finally, Prosight Management LP boosted its position in Kezar Life Sciences by 25.5% in the third quarter. Prosight Management LP now owns 52,331 shares of the company’s stock valued at $1,120,000 after buying an additional 10,640 shares during the last quarter. 48.89% of the stock is currently owned by institutional investors.

Kezar Life Sciences Company Profile

Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of small molecule therapeutics to treat unmet needs in autoimmunity and cancer in the United States. Its lead product candidate, KZR-616, a selective immunoproteasome inhibitor that is in Phase 1b/2 clinical trials in lupus and lupus nephritis The company was incorporated in 2015 and is headquartered in South San Francisco, California.

See Also: Bond

Get a free copy of the Zacks research report on Kezar Life Sciences (KZR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Kezar Life Sciences (NASDAQ:KZR)

Receive News & Ratings for Kezar Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kezar Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.